Cobra7 : RedHill Biopharma (NASDAQ / TASE: RDHL)
hier eine sehr interessante Biotechaktie mit einer noch interessanteren Pipeline
RHB-105 - A combination therapy for Helicobacter pylori infection, with successful top-line results from a first Phase III study.
RHB-104 – A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway, and for multiple sclerosis, with a Phase IIa proof of concept study underway.
BEKINDA™ (RHB-102) – A once-daily oral pill formulation of ondansetron, with a Phase III study underway in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted to the UK MHRA in December 2014.
RHB-106 – An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.
ABC294640 – A Phase II-stage orally-administered SK2 inhibitor targeting multiple inflammatory-GI diseases and related oncology indications
MESUPRON® – A Phase II uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers.
RP101 – A Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers, currently subject to an option-to-acquire by RedHill.
RIZAPORT™ (RHB-103) – An oral thin film formulation of rizatriptan, for the treatment of acute migraines, with a U.S. NDA under review by the FDA and a European marketing application submitted to the German BfArM in October 2014.
link für die Presentation:
link für die News: